SIMCERE PHARMA (02096) saw its shares climb more than 3% during the trading session. At the time of writing, the stock was up 2.93%, trading at HKD 12.64, with a turnover of HKD 237.223 million.

Recently, SIMCERE PHARMA announced that a subsidiary of the group has entered into an overseas licensing option agreement with an affiliate of AbbVie Inc. for the investigational new drug candidate SIM0500. Under the terms of the agreement, the group will receive an upfront payment from AbbVie, along with potential option exercise fees and milestone payments totaling up to USD 1.055 billion. The agreement also includes tiered royalties on net sales.

A recent research report from Guojin Securities stated that SIMCERE PHARMA (02096) continues to intensify its innovation transformation, with multiple innovative pipelines being licensed overseas. Taking into account the confirmation of upfront and milestone payments in 2026, the firm has raised its revenue and profit forecasts for 2026, while maintaining its profit forecasts for 2025 and 2027. It is estimated that total operating revenue for 2025-2027 will be RMB 7.63 billion, RMB 10.03 billion, and RMB 11.04 billion, respectively (previously RMB 7.63 billion, RMB 9.10 billion, and RMB 11.04 billion). Net profit attributable to shareholders is projected to be RMB 1.15 billion, RMB 1.65 billion, and RMB 1.66 billion (previously RMB 1.15 billion, RMB 1.38 billion, and RMB 1.66 billion), with corresponding EPS of RMB 0.44, RMB 0.64, and RMB 0.64 (previously RMB 0.44, RMB 0.53, and RMB 0.64). The "Buy" rating has been maintained.